There is currently no treatment for MPS IVA other than supportive care for the clinical
manifestations of the disease. Enzyme replacement therapy (ERT) with BMN 110 to replace the
deficient GALNS is a potential new treatment option for MPS IVA patients. BMN 110, containing
recombinant human GALNS (rhGALNS) developed by BioMarin is expected to reduce the
progressive, pathologic accumulation of KS, and improve signs and symptoms of the disease.
The objective of this Phase 3B open label study (110-502) will be to evaluate the safety and
tolerability of 2.0 mg/kg/week (qw) of BMN 110 in Australian patients with MPS IVA. In
addition, a number of secondary and tertiary efficacy endpoints will also be investigated.
The dose and regimen of BMN 110 have been selected on the basis of data from a Phase 1/2
clinical study with BMN 110, nonclinical and in vitro studies with BMN 110, and clinical and
nonclinical data from other enzyme replacement therapies.
Extension Phase is included per amendment dated 10Mar 2014: To provide patients enrolled in
the Initial Phase access to BMN 110 until commercial product becomes available in Australia
and continue to assess long-term safety